杜皮卢马布治疗调节了患有 Prurigo Nodularis 的患者的循环炎症媒介
Aaron Bao1,2,3, Emily Ma1,2,3, Hannah Cornman1,2,3
1Department of Dermatology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
概括
杜皮卢马布治疗显著降低了结节炎 (PN) 患者的全身炎症蛋白质. 这表明dupilumab可以通过准关键的免疫和纤维化通路来帮助管理PN并发症.
科学领域:
- 免疫学 免疫学 免疫学
- 皮肤病学 皮肤病学
- 系统性炎症 系统性炎症
背景情况:
- 鼻结节 (PN) 是一种慢性炎症性皮肤疾病,伴有强烈的和结节.
- 延后性瘤涉及系统性炎症,可能与并发症有关.
- 杜比卢马布对PN系统性炎症的影响尚不清楚.
研究的目的:
- 在PN患者中,研究在dupilumab治疗后血炎性蛋白质的变化.
- 探索dupilumab对全身炎症和相关途径的潜在影响.
主要方法:
- 探索性研究分析了来自3名中度至重度PN患者的血样本.
- 在杜皮卢马布治疗≥6个月之前和之后采集的样本.
- 对2569种蛋白质的蛋白质组分析和基因组变异分析.
主要成果:
- 杜皮卢马布治疗使所有患者的临床状况显著改善.
- 治疗后有186种蛋白质的差异表达,显着降低了Th1,Th2和Th17/Th22细胞因子的下调.
- 观察到先天免疫,免疫细胞迁移和纤维化的标志物减少.
- 降低了Th2,Th17和上皮层-介质细胞过渡的途径表达.
结论:
- 杜皮卢马布可能会降低PN患者的全身炎症蛋白.
- 这种减少涉及多个免疫和纤维化途径.
- 杜皮卢马布可能会调节PN的全身性病并发症的发展.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
130
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
130
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
156
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
156
Inflammatory Bowel Disease IV: Pharmacological Management
125
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
125
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
115
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
115


